Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The company is planning to expand its plant capacity in in Vapi
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
The Unit has been issued GMP Certification from ANVISA-Brazil
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Shares and American Depositary Shares of Olink for $26.00 per Share
AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
The academy has secured partnerships with 15 esteemed hospitals
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Subscribe To Our Newsletter & Stay Updated